



JC10 Rec'd PCT/PTO 11 JUL 2005

PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

KITA et al.

Serial No. ~~10/536,805~~

Filed: May 27, 2005

Atty. Ref.: 1035-590

TC/A.U.: unknown

Examiner: unknown

For: CONNEXIN 26 INHIBITOR AND CANCER METASTASIS INHIBITOR

\* \* \* \* \*

July 11, 2005

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

As suggested by 37 C.F.R. 1.97, the undersigned attorney brings to the attention of the Patent and Trademark Office the references listed on the attached form PTO-1449. A copy of the cited references are attached.

This is not to be construed as a representation that a search has been made or that no better prior art exists, or that a reference is relevant merely because cited.

The Examiner is requested to initial the attached form PTO-1449 and to return a copy of the initialed document to the undersigned as an indication that the attached references have been considered and made of record.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By:

Frank P. Presta  
Reg. No. 19,828

FPP:alb  
901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

## **INFORMATION DISCLOSURE · CITATION**

Y. DOCKET NO.

SERIALS.

unknown



(Use several sheets if necessary)

JUL 11 2015 ING DATE

TG/A II

RECEIVED  
JULY 9

10/A.3.

May 27, 2005

unknown

## U.S. PATENT DOCUMENTS

## **FOREIGN PATENT DOCUMENTS**

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function" Levon M. Khachigian, The Journal of Clinical Investigation, November 2000, vol. 106, No. 10, pp1189-1195.
	"Chemical requirements for inhibition of gap junction communication by the biologically active lipid oleamide" Dale L. Boger et al., Proc. Natl. Acad. Sci. USA, vol 95, April 1998, pp4810-4815.
	"Negative Growth Control of HeLa Cells by Connexin Genes: Connexin Species Specificity" M. Mesnil et al., CANCER RESEARCH 55, February 1, 1995, pp629-639.
	"Dominant-negative abrogation of connexin-mediated cell growth control by mutant connexin genes" Agnès Duflot-Dancer et al., Oncogene (1997) 15, pp2151-2158, © 1997 Stockton Press.
	"v-Crk activates the phosphoinositide 3-kinase/AKT pathway in transformation" Tsuyoshi Akagi et al., PNAS, June 20, 2000, vol. 97, No. 13, pp7290-7295.
	"Mutated Connexin43 Proteins Inhibit Rat Glioma Cell Growth Suppression Mediated by Wild-Type Connexin43 In A Dominant-Negative Manner" Yasufumi OMORI et al., Int. J. Cancer: 78, pp446-453 (1998), © 1998 Wiley-Liss, Inc

**\*Examiner**

### Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.